Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Heart

• Publication date

  2011-09-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/hrt.2011.223867PMID 21900585
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• If the radial artery is the new standard of care in primary percutaneous coronary intervention, why is most intervention done by the femoral approach?

  2011cited by this paper
• High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study.

  2011influential reference
• Erythropoietin in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Randomized, Double-Blind Trial

  2010cited by this paper
• Cardiac preconditioning for ischaemia: lost in translation

  2010cited by this paper
• Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study -.

  2010cited by this paper
• A single dose of erythropoietin in ST-elevation myocardial infarction.

  2010cited by this paper
• Thrombotic complications of erythropoiesis-stimulating agents.

  2010cited by this paper
• Absence of functional EpoR expression in human tumor cell lines.

  2010cited by this paper
• Influenza and cardiovascular disease: does swine-origin, 2009 H1N1 flu virus represent a risk factor, an acute trigger, or both?

  2010cited by this paper
• Erythropoietin: not just about erythropoiesis.

  2010cited by this paper
• Transradial access for primary percutaneous coronary intervention: the next standard of care?

  2010cited by this paper
• Primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: changing patterns of vascular access, radial versus femoral artery

  2009cited by this paper
• Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study.

  2009cited by this paper
• Quantification of myocardial area at risk with T2-weighted CMR: comparison with contrast-enhanced CMR and coronary angiography.

  2009cited by this paper
• Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction.

  2009cited by this paper
• Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke

  2009cited by this paper
• Microvascular obstruction after percutaneous coronary intervention

  2009cited by this paper
• Erythropoietin: ready for prime-time cardioprotection.

  2008influential reference
• Effect of cyclosporine on reperfusion injury in acute myocardial infarction.

  2008cited by this paper
• Endogenous erythropoietin and a single bolus of 40,000 IU of epoetin alpha do not protect the heart from ischaemia-reperfusion injury during extracorporeal circulation for cardiac surgery

  2008cited by this paper
• Determinants and impact of microvascular obstruction in successfully reperfused ST-segment elevation myocardial infarction. Assessment by magnetic resonance imaging

  2007cited by this paper
• Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial.

  2007cited by this paper
• Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging.

  2007cited by this paper
• Myocardial reperfusion injury.

  2007cited by this paper
• Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion.

  2007cited by this paper
• High-dose Erythropoietin Has No Long-term Protective Effects in Sheep with Reperfused Myocardial Infarction

  2006cited by this paper
• A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study

  2006cited by this paper
• Expression of the erythropoietin receptor in human heart.

  2005cited by this paper
• Postconditioning the Human Heart

  2005cited by this paper
• Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging.

  2005cited by this paper
• Myocardial Reperfusion Injury

  2004influential reference
• Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial

  2002influential reference
• Serial Magnetic Resonance Imaging of Global and Regional Left Ventricular Remodeling during 1 Year after Acute Myocardial Infarction

  2001cited by this paper
• Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction.

  1998cited by this paper
• Clinical Implications of the ‘No Reflow’ Phenomenon

  1996cited by this paper
• Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction.

  1996cited by this paper

• Therapeutic interventions for coronary microvascular obstruction after acute myocardial infarction: Developments and challenges.

  2026cites this paper
• Cationic microbubble loading hSIRT3 and hTIMP3 optimize cardiac-targeted delivery and myocardial protection in the porcine MI/R model

  2025cites this paper
• The temporal impact of erythropoietin administration on mitochondrial function and dynamics in cardiac ischemia/reperfusion injury.

  2022cites this paper
• Growth factor for therapeutic angiogenesis in ischemic heart disease: A meta-analysis of randomized controlled trials

  2022influential citation
• Translational Block in Stroke: A Constructive and “Out-of-the-Box” Reappraisal

  2021cites this paper
• Pharmacologic Prevention of Myocardial Ischemia-Reperfusion Injury in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

  2021cites this paper
• Erythropoietin Receptor/β Common Receptor: A Shining Light on Acute Kidney Injury Induced by Ischemia-Reperfusion

  2021cites this paper
• Acute myocardial infarction and cardiogenic shock: Should we unload the ventricle before percutaneous coronary intervention?

  2020cites this paper
• Erythropoietin Doping: Cardiovascular Effects in Athletes

  2020cites this paper
• HBSP protects cardiomyocytes from hypoxia/reoxygenation-induced autophagy through the PI3K/Akt pathway.

  2020cites this paper
• Effects of Epoetin Alfa in STEMI patients Long term effects of Epoetin Alfa in patients with ST- elevation myocardial infarction

  2019cites this paper
• Erythropoietin Therapy in Critically Ill and Acute Kidney Injury Patients

  2019cites this paper
• coronarios agudos ( IV ) Protección contra el daño miocárdico por isquemia-reperfusión en la práctica clı́nica

  2019cites this paper
• Coronary microvascular obstruction: the new frontier in cardioprotection

  2019cites this paper
• Microvascular Obstruction in ST-Segment Elevation Myocardial Infarction: Looking Back to Move Forward. Focus on CMR

  2019cites this paper
• Defining left ventricular remodeling following acute ST-segment elevation myocardial infarction using cardiovascular magnetic resonance

  2017cites this paper
• Intracoronary Hypothermia Before Reperfusion to Reduce Reperfusion Injury in Acute Myocardial Infarction: A Novel Hypothesis and Technique

  2017cites this paper
• Harms of off-label erythropoiesis-stimulating agents for critically ill people.

  2017cites this paper
• The Erythropoietin System Protects the Heart Upon Injury by Cardiac Progenitor Cell Activation.

  2017cites this paper
• The effect of remote ischaemic preconditioning on contrast induced nephropathy in the clinical setting of coronary angiography and percutaneous coronary intervention

  2017cites this paper
• Targeting mitochondrial permeability as a pharmacological cardioprotective strategy.

  2017cites this paper
• Serum uromodulin predicts graft failure in renal transplant recipients

  2017cites this paper
• Circadian variation in acute myocardial infarct size assessed by cardiovascular magnetic resonance in reperfused STEMI patients

  2017cites this paper
• Baseline Hemoglobin Levels Associated with One-Year Mortality in ST-Segment Elevation Myocardial Infarction Patients.

  2016cites this paper
• The use of pharmacological conditioning strategies to improve donor heart preservation in cardiac transplantation

  2016cites this paper
• Helix B Surface Peptide Protects Cardiomyocytes Against Hypoxia/Reoxygenation-induced Apoptosis Through Mitochondrial Pathways

  2016cites this paper
• Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery

  2016cites this paper
• Helix B Surface Peptide Protects against Acute Myocardial Ischemia-Reperfusion Injury via the RISK and SAFE Pathways in a Mouse Model

  2016cites this paper
• Sub-anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial

  2016cites this paper
• Almanac 2012: Interventional cardiology Almanaque 2012: Cardiología intervencionista

  2016cites this paper
• Administration of erythropoietin in patients with myocardial infarction: does it make sense? An updated and comprehensive meta-analysis and systematic review.

  2015cites this paper
• Testosterone replacement therapy : cardiovascular benefits and possible risks .

  2015cites this paper
• Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury.

  2015cites this paper
• Improving myocardial injury, infarct size, and myocardial salvage in the era of primary PCI for STEMI

  2015cites this paper
• Measuring myocardial salvage: hormone cardioprotection

  2015cites this paper
• Ischaemic postconditioning: cardiac protection after the event

  2015cites this paper
• Infarct size reduction in acute myocardial infarction

  2014cites this paper
• Protection against myocardial ischemia-reperfusion injury in clinical practice.

  2014cites this paper
• Protección contra el daño miocárdico por isquemia-reperfusión en la práctica clínica ☆

  2014cites this paper
• Pharmacologic Therapy That Simulates Conditioning for Cardiac Ischemic/Reperfusion Injury

  2014cites this paper
• Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: a meta-analysis of individual patient data.

  2014cites this paper
• High‐dose erythropoietin for tissue protection

  2014cites this paper
• Erythropoietin and the heart: physiological effects and the therapeutic perspective.

  2014cites this paper
• Erythropoietin Therapy for Heart Failure

  2014cites this paper
• Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis

  2013cites this paper
• Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.

  2013cites this paper
• Outcome after percutaneous coronary intervention

  2013cites this paper
• What is the Role of Erythropoietin in Acute Myocardial Infarct? Bridging the Gap Between Experimental Models and Clinical Trials

  2013cites this paper
• Myocardial ischemia-reperfusion injury: a neglected therapeutic target.

  2013cites this paper
• Impact of Erythropoietin on Intensive Care Unit Patients

  2013cites this paper
• Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction

  2013cites this paper
• High-Dose Erythropoietin in Acute ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials

  2013influential citation
• High-dose intravenous epoetin does not increase blood pressure in critically ill patients with acute kidney injury.

  2013cites this paper
• Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: results of the randomized Intra-Co-EpoMI trial.

  2013cites this paper
• Erythropoietin in cardiac disease: effective or harmful?

  2013cites this paper
• Erythropoietin and the vascular wall: the controversy continues.

  2013cites this paper
• Therapy against ischemic injury.

  2013cites this paper
• CPP-conjugated anti-apoptotic peptides as therapeutic tools of ischemia-reperfusion injuries.

  2013cites this paper
• A single-center prospective randomized controlled trial evaluating the safety and efficacy of IntraCoronary Erythropoietin delivery BEfore Reperfusion: gauging infarct size in patients with acute ST-segment elevation myocardial infarction. Study design and rationale of the 'ICEBERG Trial'.

  2013cites this paper
• Almanac 2012: Cardiovascular risk scores: The national society journals present selected research that has driven recent advances in clinical cardiology

  2013cites this paper
• Effects of Erythropoietin on Blood Vessels and the Heart

  2013cites this paper
• Almanah 2012.: intervencijska kardiologija. »asopisi nacionalnih druπtava predstavljaju odabrana istraæivanja koja donose napredak u kliniËkoj kardiologiji Almanac 2012: interventional cardiology. The national society journals present selected research that has driven recent advances in clinical car

  2013cites this paper
• Twenty-First Annual Scientific Congress

  2013cites this paper
• Almanac 2012: Interventional Cardiology. The National Society Journals present selected research that has driven recent advances in clinical cardiology.

  2013cites this paper
• Almanac 2012: Interventional cardiology.

  2013cites this paper
• The national society journals present selected research that has driven recent advances in clinical cardiology

  2013cites this paper
• Novel treatment strategies

  2012cites this paper
• Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.

  2012cites this paper
• Imaging the Myocardial Microcirculation Post-Myocardial Infarction

  2012cites this paper
• Organ-protective and immunomodulatory effects of erythropoietin--an update on recent clinical trials.

  2012cites this paper
• Conditioning the heart to prevent myocardial reperfusion injury during PPCI

  2012cites this paper
• Almanac 2012: interventional cardiology: The national society journals present selected research that has driven recent advances in clinical cardiology

  2012cites this paper
• Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy

  2012cites this paper
• Conditioning the whole heart--not just the cardiomyocyte.

  2012cites this paper
• Cardioprotection during cardiac surgery.

  2012cites this paper
• Almanac 2012: interventional cardiology.

  2012cites this paper
• The Mitochondria-Targeted Antioxidants and Remote Kidney Preconditioning Ameliorate Brain Damage through Kidney-to-Brain Cross-Talk

  2012cites this paper
• CMR of microvascular obstruction and hemorrhage in myocardial infarction

  2012cites this paper
• Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning

  2012cites this paper
• Quelles potentialités thérapeutiques pour l’érythropoiétine recombinante dans le traitement des traumatismes du système nerveux central ?

  2012cites this paper
• 2 Indicators of perioperative myocardial injury and infarction in cardiac surgery

  2012cites this paper
• Australian and New Zealand Resuscitation Councils : October 2011 Research Updates

  2011cites this paper
• Erythropoietin as a cardioprotective agent: down but not out

  2011influential citation